These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 37481836)

  • 1. Immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: A systematic review.
    Attili I; Passaro A; Corvaja C; Trillo Aliaga P; Del Signore E; Spitaleri G; de Marinis F
    Cancer Treat Rev; 2023 Sep; 119():102602. PubMed ID: 37481836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Immune Checkpoint Inhibitor Therapy in Advanced
    Wiest N; Majeed U; Seegobin K; Zhao Y; Lou Y; Manochakian R
    Front Oncol; 2021; 11():751209. PubMed ID: 34868953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.
    Dafni U; Tsourti Z; Vervita K; Peters S
    Lung Cancer; 2019 Aug; 134():127-140. PubMed ID: 31319971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic review and network meta-analysis of first-line immune checkpoint inhibitor combination therapies in patients with advanced non-squamous non-small cell lung cancer.
    Shao T; Zhao M; Liang L; Tang W
    Front Immunol; 2022; 13():948597. PubMed ID: 36389713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of immune checkpoint inhibitors in EGFR-Mutant NSCLC patients with EGFR-TKI resistance: A systematic review and meta-analysis.
    Qian X; Guo X; Li T; Hu W; Zhang L; Wu C; Ye F
    Front Pharmacol; 2022; 13():926890. PubMed ID: 36071838
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy and safety of immune checkpoint inhibitors in post-TKI NSCLC patients harboring EGFR mutations.
    Sun S; Liu C; Duan C; Yu S; Zhang Q; Xu N; Yu B; Wu X; Wang J; Hu X; Yu H
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):2937-2949. PubMed ID: 35835883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of immune checkpoint inhibitors in EGFR-mutant non-small-cell lung cancer: from bed to bench.
    Jin R; Zhao J; Xia L; Li Q; Li W; Peng L; Xia Y
    Ther Adv Med Oncol; 2020; 12():1758835920930333. PubMed ID: 32565926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with or without PD-L1 selection: A systematic review and network meta-analysis.
    Li Y; Liang X; Li H; Chen X
    Chin Med J (Engl); 2023 Sep; 136(18):2156-2165. PubMed ID: 37596898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of ICI-based treatment in advanced NSCLC patients with PD-L1≥50% who developed EGFR-TKI resistance.
    Li Y; Jiang H; Qian F; Chen Y; Zhou W; Zhang Y; Lu J; Lou Y; Han B; Zhang W
    Front Immunol; 2023; 14():1161718. PubMed ID: 37266427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identifying optimal first-line immune checkpoint inhibitors based regiments for advanced non-small cell lung cancer without oncogenic driver mutations: A systematic review and network meta-analysis.
    Liu T; Wu S; Fang W; Li H; Su L; Qi G; Li H; Liu Y
    PLoS One; 2023; 18(4):e0283719. PubMed ID: 37071610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Front-Line ICI-Based Combination Therapy Post-TKI Resistance May Improve Survival in NSCLC Patients With EGFR Mutation.
    Tian T; Yu M; Li J; Jiang M; Ma D; Tang S; Lin Z; Chen L; Gong Y; Zhu J; Zhou Q; Huang M; Lu Y
    Front Oncol; 2021; 11():739090. PubMed ID: 34888234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer.
    Kawachi H; Yamada T; Tamiya M; Negi Y; Goto Y; Nakao A; Shiotsu S; Tanimura K; Takeda T; Okada A; Harada T; Date K; Chihara Y; Hasegawa I; Tamiya N; Ishida M; Katayama Y; Morimoto K; Iwasaku M; Tokuda S; Kijima T; Takayama K
    JAMA Netw Open; 2023 Jul; 6(7):e2322915. PubMed ID: 37432682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcomes of immune checkpoint inhibitors to treat non-small cell lung cancer patients harboring epidermal growth factor receptor mutations.
    Si J; Hao Y; Wei J; Xiang J; Xu C; Shen Q; Song Z
    BMC Pulm Med; 2023 May; 23(1):158. PubMed ID: 37147602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of immune checkpoint inhibitor therapy in EGFR mutation-positive patients with NSCLC and brain metastases who have failed EGFR-TKI therapy.
    Zhou S; Ren F; Meng X
    Front Immunol; 2022; 13():955944. PubMed ID: 36238280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Efficacy of Neoadjuvant Immune Checkpoint Inhibitor Therapy in Patients with Resectable Non-small-Cell Lung Cancer: A Systematic Review.
    Zhao Z; Gao Y; Xue Q; Gao S; He J
    Target Oncol; 2021 Jul; 16(4):425-434. PubMed ID: 33983556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hope and Challenges: Immunotherapy in
    Yan D
    Biomedicines; 2023 Oct; 11(11):. PubMed ID: 38001917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Differences in the Safety and Tolerability of Immune Checkpoint Inhibitors as Treatment for Non-Small Cell Lung Cancer and Melanoma: Network Meta-Analysis and Systematic Review.
    Chai QQ; Du JY; Zhu J; Wu B
    Front Pharmacol; 2019; 10():1260. PubMed ID: 31708783
    [No Abstract]   [Full Text] [Related]  

  • 18. PD-1 inhibitors plus chemotherapy in EGFR/ALK-positive NSCLC patients with brain metastases and disease progression after EGFR/ALK-TKIs therapy.
    Zhu Y; Zhang Y; Hu X; Wang M; Wang H; Liu Y
    J Cancer Res Clin Oncol; 2022 Dec; 148(12):3557-3566. PubMed ID: 35857126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Real-World Analysis of Immune Checkpoint Inhibitor-Based Therapy After Osimertinib Treatment in Patients With
    Morimoto K; Sawada R; Yamada T; Azuma K; Ito K; Goto Y; Kimura H; Harada T; Shiotsu S; Tamiya N; Chihara Y; Takeda T; Hiranuma O; Hasegawa I; Morimoto Y; Iwasaku M; Tokuda S; Takayama K
    JTO Clin Res Rep; 2022 Sep; 3(9):100388. PubMed ID: 36082280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in NSCLC Harboring ERBB2 Mutations.
    Saalfeld FC; Wenzel C; Christopoulos P; Merkelbach-Bruse S; Reissig TM; Laßmann S; Thiel S; Stratmann JA; Marienfeld R; Berger J; Desuki A; Velthaus JL; Kauffmann-Guerrero D; Stenzinger A; Michels S; Herold T; Kramer M; Herold S; Tufman A; Loges S; Alt J; Joosten M; Schmidtke-Schrezenmeier G; Sebastian M; Stephan-Falkenau S; Waller CF; Wiesweg M; Wolf J; Thomas M; Aust DE; Wermke M;
    J Thorac Oncol; 2021 Nov; 16(11):1952-1958. PubMed ID: 34245914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.